PMID- 23377811
OWN - NLM
STAT- MEDLINE
DCOM- 20130614
LR  - 20181202
IS  - 1128-3602 (Print)
IS  - 1128-3602 (Linking)
VI  - 17
IP  - 2
DP  - 2013 Jan
TI  - Preparation of microencapsulated VEGF gene-modified human umbilical cord 
      mesenchymal stem cells and in vitro culture.
PG  - 217-23
LID - 2948 [pii]
AB  - BACKGROUND AND OBJECTIVES: The application of microencapsulated stem cells has 
      been shown to have many advantages in various fields of medical research. 
      However, optimal modes for preparation of microencapsulate stem cells need to be 
      improved, and expression and release of products of microencapsulated gene 
      modified stem cells need to be studied in vitro. AIM OF THE STUDY: To explore the 
      optimal parameters when preparing microencapsulated stem cells, and to 
      investigate the effect of microencapsulation on growth, secretion, and metabolism 
      of genetically modified human Umbilical Cord Mesenchymal Stem Cells (hUCMSCs). 
      MATERIALS AND METHODS: In this study, the parameters of preparation were 
      regulated by observing the microcapsule shape and size. Live/dead cell viability 
      kits and fluorescein isothiocyanate-labeled dextrans (FD) were used to detect the 
      microencapsulated cell viability, and the permeability of microcapsules, 
      respectively. Vascular endothelial growth factor (VEGF) production in the 
      supernatant of microencapsulated and non-microencapsulated VEGF gene-modified 
      hUCMSCs cultures was measured by ELISA. RESULTS: The optimal parameters of 
      preparing microcapsules were regulated as followed: bolus velocity was 6 ml/h, 
      and airflow velocity was 3 L/min. The morphology of microcapsules was a spherical 
      structure with a diameter of 450 +/- 30 microm. More than 90% of the cells were viable 
      after 21 days of culture. Low and middle molecular weight FD was able to pass 
      through the microcapsules; however, high molecular weight FD was not. Also, the 
      VEGF concentration in microencapsulated and non-microencapsulated cell culture 
      supernatants exhibited no significant difference at each time point. CONCLUSIONS: 
      Microencapsulated stem cells can be ideally prepared via specifically regulated 
      preparation. Lastly, microencapsulation does not alter growth, secretion, and 
      metabolism of the genetically modified hUCMSCs.
FAU - Han, Y-F
AU  - Han YF
AD  - Department of Plastic Surgery, Affiliated Beijing Shijitan Hospital, Capital 
      Medical University, Beijing, People's Republic of China.
FAU - Sun, T-J
AU  - Sun TJ
FAU - Han, Y-Q
AU  - Han YQ
FAU - Tao, R
AU  - Tao R
FAU - Chai, J-K
AU  - Chai JK
FAU - Yin, H-N
AU  - Yin HN
FAU - Xu, G
AU  - Xu G
FAU - Liu, J
AU  - Liu J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Cell Survival
MH  - Cells, Cultured
MH  - Drug Compounding
MH  - Humans
MH  - Mesenchymal Stem Cells/*cytology/physiology
MH  - Permeability
MH  - Umbilical Cord/*cytology
MH  - Vascular Endothelial Growth Factor A/*genetics
EDAT- 2013/02/05 06:00
MHDA- 2013/06/15 06:00
CRDT- 2013/02/05 06:00
PHST- 2013/02/05 06:00 [entrez]
PHST- 2013/02/05 06:00 [pubmed]
PHST- 2013/06/15 06:00 [medline]
AID - 2948 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2013 Jan;17(2):217-23.